Public Hearing on CDER's Current Risk Communication Strategies
for Human Drugs, December 7-8, 2005
National Transportation Safety Board Boardroom and Conference Center
429 L’Enfant Plaza SW, Washington, DC 20594

On December 7-8, 2005, FDA's Center for Drug Evaluation and Research (CDER) will hold a public hearing on the CDER's current risk communication strategies for human drugs. The public hearing is part of the Agency’s ongoing effort to improve CDER’s risk communication. The purpose of the hearing is to obtain public input on CDER’s current risk communication tools, identify stakeholders for collaboration and implementation of additional tools, and obtain greater understanding of the strengths and weaknesses of CDER’s existing risk communication.

• CDER Center Director Meeting Announcement (10/3/2005)
• Federal Register Notice of Public Meeting [HTML] or [PDF] (10/3/2005)
• Agenda
• Summary of Public Hearing (1/23/2006)
• Meeting Transcripts (1/9/2006)
  • December 7
  • December 8

Dates: December 7 and 8, 2005
Time:  8:00 a.m. to 4:30 p.m.
Location:  National Transportation Safety Board Boardroom and Conference Center, 429 L’Enfant Plaza SW, Washington, DC 20594.  (Metro: L’Enfant Plaza Station on the Green, Yellow, Blue, and Orange Lines)  directions

Submit written or electronic notices of participation (registration) and comments for consideration at the hearing by November 7, 2005. Written or electronic comments will be accepted after the hearing until January 9, 2006. The administrative record of the hearing will remain open until January 9, 2006.

Send Comments:

• Mailing Address:
  Division of Dockets Management (HFA-305)
  Food and Drug Administration,
  5630 Fishers Lane, Room 1061
  Rockville, Maryland 20852
• E-mail Address: FDADockets@oc.fda.gov
• Internet: Dockets Open for Comment

Register for the Public Meeting (Only speakers need to register.)

• Mailing Address:
  Division of Dockets Management (HFA-305)
  Food and Drug Administration,
  5630 Fishers Lane, Room 1061
  Rockville, Maryland 20852
• E-mail Address: FDADockets@oc.fda.gov
• Internet: Register (Registration required for speakers only)

Transcripts of the hearing will be available for review at the Division of Dockets Management and on the Internet on the Dockets Management Site approximately 30 days after the hearing.

For further information, contact:
Lee Lemley,
Office of Executive Programs (HFD-006)
Center for Drug Evaluation and Research
Food and Drug Administration,
5515 Security Lane, Room 7232
Rockville, Maryland 20852
301-443-5392

Directions to the NTSB Conference Center from Metro Station:

• Take Metro to L'Enfant Plaza Station.
• After exiting the train, follow signs to L'Enfant Plaza (Do not follow signs to U.S. Dept .of Transportation).
• Take escalator to the top and turn right. Go as far as you can and go through the glass doors on the left to enter La Promenade.
• Go straight for about 200 feet and turn right.
• Go straight ahead, across the atrium and continue straight ahead until you reach the escalators by the CVS store.
• Take the right escalator down and turn 180 degrees left.
• The NTSB Conference Center is right in front of you.

NTSB driving directions and map

PDF requires the free Adobe Acrobat Reader

Back to Top     Back to CDER Workshops

Date created: October 3, 2005, updated January 23, 2006

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research